RV

Rahul Kumar Verma

Also known as: Principal Scientist

Institute of Nano Science and Technology: Mohali, Punjab, IN, Harvard Medical School, Central Drug Research Institute, National Institute of Pharmaceutical Education and Research

ORCID iD 0000-0003-0719-8227
Follow

About

Dr. Rahul Kumar Verma is a distinguished pharmaceutical scientist known for his contributions to the field of Pharmaceutical nanotechnology. He is widely recognized for his pioneering research in inhalation drug delivery systems and nanomedicine, which has significantly advanced the efficacy and safety of pharmaceutical treatments. Driven by a desire to delve deeper into the realm of drug development, Dr. Verma pursued further studies and obtained his Master's and Doctoral degrees in Pharmaceutical Sciences from reputed National Institute of pharmaceutical Education and Research (NIPER) SAS Nagar and Central Drug Research Institute, India. Subsequently, he pursued postdoctoral studies from Oklahoma University USA and Harvard Medical School, Boston, USA. Dr. Verma's research endeavors have encompassed a wide range of therapeutic areas, including Tuberculosis, Cold injury, cancer, infectious diseases, and arthritic disorders. His innovative approaches have resulted in the development of nano-formulations capable of enhancing the bioavailability and therapeutic efficacy of conventional drugs while minimizing adverse effects.

Employment

  • Harvard Medical School Research Fellow
    2023 - 2024
  • Institute of Nano Science and Technology: Mohali, Punjab, IN Associate Professor
    2021 - Present
  • Institute of Nano Science and Technology Scientist D ( Assistant Professor)
    2017 - 2020
  • Institute of Nano Science and Technology Scientist C
    2014 - 2017
  • University of Oklahoma Health Sciences Center Post Doctoral Fellow
    2013 - 2014

Education

  • Central Drug Research Institute PhD
    2009 - 2013
  • National Institute of Pharmaceutical Education and Research M.S ( Pharma)
    2003 - 2005

Projects & Funding

Projects & funding information is unavailable.

Publications (70)